Lowest Price Guaranteed From USD 4,799
Published
October 2022
Pages
272
View Count
19235
Example Insights
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
Report Description
The global mRNA therapeutics and mRNA vaccine market size was estimated to be worth over USD 51 billion in 2022; non COVID-19 indications will drive the market growth during the forecast period 2023-2035. Messenger ribonucleic acid (mRNA) is a type of single-stranded ribonucleic acid (RNA), which helps in transferring genetic information in order to produce proteins. The mRNA encoding instructions for protein synthesis are transferred from a strand of DNA to the ribosomes, where these instructions are translated and processed into functional proteins. mRNA therapeutics and mRNA vaccines have emerged as a promising alternative to conventional treatment approaches. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccine have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as infectious diseases, cancer, genetic disorders and other disorders. Till date, three mRNA-based vaccines have received approval for the treatment of COVID-19, while a number of such candidates are being evaluated as potential therapies. Moreover, BioNTech and Pfizer have signed contracts to deliver 2.4 billion doses of its approved vaccine, Comirnaty®, by the end of 2022. The overall success of the mRNA-based therapies and vaccines against COVID-19 has attracted the interest of several investors, specifically towards small and emerging mRNA focused biotechnology companies.
The mRNA Therapeutics and mRNA Vaccine Market (2nd Edition), 2022-2035: Distribution by Route of Administration (Intravenous, Intramuscular, Intranasal and Others), Therapeutic Area (Infectious Diseases, Oncological Disorders and Other Disorders), and Geography (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa) report features an extensive study of the current market overview and future potential of the mRNA therapeutics and vaccines market, over the forecast period. The study also features an in-depth analysis, highlighting the capabilities of various mRNA companies engaged in this field. Amongst other elements, the market research report analyzes the mRNA market from the perspective of drugs developers, manufacturers, mRNA technology companies and investors.
The ongoing research and development efforts being undertaken in the mRNA therapeutics market are primarily being driven by the various advantages offered by these molecules, including higher biological efficacy, enhanced potent immunogenicity and versatile delivery platforms at reduced toxicity levels, over other therapeutic modalities. Recent reports highlight the potential benefits related to the use of mRNA; for instance, such products pose no undesirable risk of inadvertent infection and insertional mutagenesis. Additionally, the in vivo half-life of mRNA can be regulated by deploying different modifications and delivery techniques in order to make the drugs more stable and highly translatable, as it is usually degraded by typical cellular activities. Moreover, owing to the high yields of in vitro transcription reactions, the manufacturing of mRNA candidates is believed to be cost-effective, rapid and scalable.
With the approval of the first mRNA vaccine under emergency use authorization (EUA), Comirnaty®, in 2020, the field has witnessed a further surge in activity. Since then, two more mRNA-based therapies under EUA, namely (in chronological order of approval year) Spikevax® (December 2020) and GEMCOVAC™-19 (June 2022), have been approved by regulatory authorities. In addition, over 70 mRNA therapeutics and mRNA vaccines are being evaluated in various stages of clinical trials for the treatment of multitude of disease indications. Amongst the mRNA-based products, majority of the development is focused on mRNA vaccines. However, mRNA companies such as Moderna, BioNTech and Arcturus Therapeutics, are also developing mRNA therapeutics. Till July 2022, AstraZeneca was developing a mRNA-based protein replacement therapy, AZD8601 (a mRNA expressing vascular endothelial growth factor (VEGF-A)), for treatment of cardiovascular disease. However, the rights for the drug were returned to Moderna, which is evaluating the next steps for the program.
Additionally, the companies are evaluating various mRNA delivery technology to ensure efficient and safe delivery of the oligonucleotide. These details along with the route of administration have been analyzed in this market report.
Presently, over 35 companies are engaged in the evaluation of more than 195 mRNA therapeutics and mRNA vaccines, across various stages of development, for a myriad of disease indications. Further, over the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Big pharmaceutical companies such as Merck, Sanofi and Daiichi Sankyo have partnered with smaller, dedicated mRNA-based therapeutics and vaccines developers to expand their respective capabilities in this upcoming field of therapy. In September 2021, Sanofi became the first big pharma to acquire a mRNA therapeutics company, Translate Bio. The active involvement of big pharma players, as well as the presence of new entrants, will drive the market growth during the forecast period.
In 2022, the mRNA therapeutics market was driven by sales of three approved mRNA vaccine for infectious diseases, particularly COVID-19. However, mRNA drugs have shown safety and efficacy against a myriad of other infectious diseases such as Respiratory Syncytial Virus Infection, Cytomegalovirus Infection and Influenza. In addition, companies such as BioNTech are also working on development of mRNA-based vaccine for mosquito-borne infectious disease, Malaria. According to the World Health Organization (WHO), there were an estimated 247 million cases of malaria in 2021 and only a single recombinant protein-based vaccine from GSK marketed to date.
Additionally, it is worth noting that the global market is likely to see the launch of first mRNA cancer vaccine by 2030. Recently, Moderna received Breakthrough Therapy Designation for its melanoma vaccine being tested in phase II clinical trial in combination with Merck’s Keytruda. Cancer targeting indications other than COVID-19 are estimated to witness lucrative market growth during the forecast period 2025-2035. This will also be driven by an increase in the incidence of cancer across the globe as well as the need to develop precision cancer therapy.
The global market for mRNA therapeutics is currently dominated by North America and this trend is unlikely to change during the forecast period. National Institutes of Health (NIH) has been supporting mRNA therapeutics research through provision of grants even before the COVID-19 pandemic. mRNA vaccine development not only requires support for the clinical development of the vaccines, but also development of delivery technologies and expansion of the manufacturing capabilities. Governments of the US and Canada are actively supporting the domestic manufacturing projects. In April 2022, Moderna announced its plan to set up a mRNA vaccine manufacturing facility in Quebec under a strategic partnership with the Government of Canada. Additionally, in September 2022, the US President signed an Executive Order to launch a National Biotechnology and Biomanufacturing Initiative, supporting domestic manufacturing. Such initiatives will continue to ensure government support for mRNA technologies and sustain the North American market share during the forecast period.
It is worth highlighting that close to 150 collaborations have been inked between industry / academic stakeholders to advance the development of their proprietary pipeline candidates. A number of big pharma companies have been part of these partnerships and have acted as active investors in emerging mRNA vaccine companies. The mRNA therapeutics market has attracted huge investments, specifically in 2020, when over USD 5 billion was invested in mRNA therapeutics companies. The raised funds are not solely focused on the development of mRNA therapeutics for infectious diseases, but cancer focused mRNA drug development efforts have also generated interest amongst the venture community.
During the period 2017-2021, the number of clinical trials registered for evaluation of mRNA-based products increased at a compounded annual growth rate (CAGR) of more than 60%. There was a significant increase in the number of patients recruited in trial studies evaluating mRNA-therapeutics, driven by the development of COVID-19 vaccine and new mRNA therapeutics and mRNA vaccines entering the clinical phase of development. Driven by the growing interest of various stakeholders and encouraging clinical research results, the overall mRNA therapeutics and mRNA vaccines market is anticipated to witness consistent market growth during the forecast period.
Several recent developments have taken place in the field of mRNA therapeutics and mRNA vaccines. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
Scope of the Report
Report Attribute | Details | |
Forecast Period |
2022 – 2035 |
|
Base Year | 2021 | |
Market Size 2022 | $51 billion | |
Area of Expertise |
mRNA therapeutics, mRNA vaccines | |
Route of Administration |
Intravenous, Intramuscular, Intranasal, Others | |
Therapeutic Areas |
Infectious diseases, Oncological disorders, Others | |
Key Geographical Regions |
North America, Europe, Asia-Pacific, MENA, Latin America and Rest of the World |
The market research report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:
One of the key objectives of this market research report was to estimate the existing market size and the future growth potential of the mRNA therapeutics and mRNA vaccines market over the forecast period. We have provided an informed estimate on the likely financial evolution of the market in the short to mid-term and long term, for the period 2022-2035. Additionally, the report features the likely distribution of the current and upcoming opportunity segmented across important parameters, such as [A] route of administration (intravenous, intramuscular, intranasal and others), [B] therapeutic area (infectious diseases, oncological disorders and other disorders), and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America, and Middle East and North Africa).
In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry’s evolution.
All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.
Contents
1. PREFACE
1.1. Scope of the Report
1.2. Market Segmentation
1.3. Research Methodology
1.4. Key Questions Answered
1.5. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. mRNA Therapeutics
3.2.1. Advantages of mRNA Therapeutics
3.2.2. Key Applications of mRNA Therapeutics
3.3. mRNA Vaccines
3.3.1. Advantages of mRNA Vaccines
3.3.2. Key Applications of mRNA Vaccines
3.4. mRNA Delivery Routes
3.5. mRNA Delivery Strategies
3.6. Key Challenges Associated with mRNA Therapeutics and Vaccines
3.7. Future Perspectives
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. mRNA Therapeutics and mRNA Vaccine: Overall Market Overview
4.2.1. Analysis by Phase of Development
4.2.2. Analysis by Type of Drug Candidate
4.2.3. Analysis by Therapeutic Area
4.2.4. Analysis by Phase of Development and Therapeutic Area
4.2.5. Analysis by Type of Delivery System Used
4.2.6. Analysis by Type of Molecule Encoded
4.2.7. Analysis by Route of Administration
4.2.8. Analysis by Therapeutic Area and Route of Administration
4.2.9. Analysis by Phase of Development, Therapeutic Area and Route of Administration (Grid Representation)
5. COMPETITIVE LANDSCAPE
5.1. mRNA Therapeutics and mRNA Vaccines: List of Companies
5.1.1. Analysis by Year of Establishment
5.1.2. Analysis by Company Size
5.1.3. Analysis by Location of Headquarters
5.1.4. Key Companies: Analysis by Number of Drug Candidates
5.1.5. Key Companies: Analysis by Number of Drug Candidates and Phase of Development
5.1.6. Key Companies: Analysis by Number of Drug Candidates and Therapeutic Area
5.1.7. Analysis by Year of Establishment, Company Size and Location of Headquarters (Heat Map Representation)
5.1.8. mRNA Therapeutics and mRNA Vaccine: Analysis by Phase of Development and Location of Headquarters (Regional Landscape)
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Key Assumptions and Parameters
6.3. Methodology
6.4. mRNA Companies: Company Competitive Analysis
6.5. mRNA Companies based in North America
6.6. mRNA Companies based in Europe
6.7. mRNA Companies based in Asia-Pacific and Rest of the World
7. DRUG PROFILES
7.1. Chapter Overview
7.2. BNT162b2 (BioNTech / Pfizer)
7.2.1. Drug Overview
7.3. GEMCOVAC-19 (Gennova)
7.3.1. Drug Overview
7.4. mRNA-1273 (Moderna)
7.4.1. Drug Overview
7.5. LUNAR-COV19 (Arcturus Therapeutics)
7.5.1. Drug Overview
7.6. CVnCOV (CureVac)
7.6.1. Drug Overview
7.7. mRNA-1010 (Moderna)
7.7.1. Drug Overview
7.8. mRNA-1345 (Moderna)
7.8.1. Drug Overview
7.9. mRNA-1647 (Moderna)
7.9.1. Drug Overview
7.10. ARCoV (Walvax)
7.10.1. Drug Overview
8. BIG PHARMA INITIATIVES
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. mRNA Related Initiatives of Big Pharmaceutical Players
8.3.1. Analysis by Portfolio Diversity
8.3.2. Analysis by Phase of Development
8.3.3. Analysis by Target Therapeutic Areas
8.4. Benchmark Analysis of Big Pharmaceutical Players
8.4.1. Spider Web Analysis: Amgen
8.4.2. Spider Web Analysis: AstraZeneca
8.4.3. Spider Web Analysis: Bayer
8.4.4. Spider Web Analysis: BioNTech
8.4.5. Spider Web Analysis: Eli Lilly
8.4.6. Spider Web Analysis: Gilead Sciences
8.4.7. Spider Web Analysis: GlaxoSmithKline
8.4.8. Spider Web Analysis: Merck
8.4.9. Spider Web Analysis: Moderna
8.4.10. Spider Web Analysis: Novartis
8.4.11. Spider Web Analysis: Novo Nordisk
8.4.12. Spider Web Analysis: Pfizer
8.4.13. Spider Web Analysis: Roche
8.4.14. Spider Web Analysis: Sanofi
8.4.15. Spider Web Analysis: Takeda
9. START-UP HEALTH INDEXING
9.1. Chapter Overview
9.2. Start-ups focused on mRNA Therapeutics and Vaccines
9.2.1. Analysis by Location of Headquarters
9.3. Benchmarking of Start-ups
9.4. Startup-Health Indexing
9.4.1. Analysis by Supplier Strength
9.4.2. Analysis by Pipeline Maturity
9.4.3. Analysis by Pipeline Strength
9.4.4. Analysis by Financial Investments
9.4.5. Analysis by Partnership Activity
9.4.6. Start-ups Health Indexing: Roots Analysis Perspective
10. CLINICAL TRIAL ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. mRNA Therapeutics and mRNA Vaccines: Clinical Trial Analysis
10.3.1. Analysis by Trial Registration Year
10.3.2. Analysis by Trial Status
10.3.3. Analysis by Trial Phase
10.3.4. Analysis by Trial Registration Year and Trial Status
10.3.5. Analysis by Trial Registration Year and Trial Phase
10.3.6. Analysis by Trial Status and Trial Phase
10.3.7. Analysis of Enrolled Patient Population by Trial Registration Year
10.3.8. Analysis by Study Design
10.3.9. Analysis by Type of Sponsor / Collaborator
10.3.10. Most Active Players: Analysis by Number of Registered Trials
10.3.11. Analysis by Therapeutic Area
10.3.12. Analysis by Number of Registered Trials and Geography
10.3.13. Analysis by Number of Registered Trials, Trial Status and Geography
10.3.14. Analysis of Enrolled Patient Population by Geography
11. PARTNERSHIPS AND COLLABORATIONS
11.1. Chapter Overview
11.2. Partnership Models
11.3. mRNA Therapeutics and mRNA Vaccine: Partnerships and Collaborations
11.3.1. Analysis by Year of Partnership
11.3.2. Analysis by Type of Partnership
11.3.3. Analysis by Year and Type of Partnership
11.3.4. Analysis by Therapeutic Area
11.3.5. Analysis by Type of Partnership and Therapeutic Area
11.3.6. Most Active Players: Analysis by Number of Partnerships
11.3.7. Regional Analysis
11.3.7.1. Intercontinental and Intracontinental Agreements
11.3.7.2. Local and International Agreements
12. FUNDING AND INVESTMENT ANALYSIS
12.1. Chapter Overview
12.2. Types of Funding
12.3. mRNA Therapeutics and mRNA Vaccines: Funding and Investment
12.3.1. Analysis by Cumulative Year-wise Trend of Funding Instances
12.3.2. Analysis by Cumulative Year-wise Trend of Amount Invested
12.3.3. Analysis by Type of Funding
12.3.4. Analysis by Year and Type of Funding
12.3.5. Analysis of Number of Funding Instances and Amount Invested by Therapeutic Area
12.3.6. Analysis of Number of Funding Instances and Amount Invested by Geography (Continent-wise)
12.3.7. Regional Analysis of Number of Funding Instances (Country-wise)
12.3.8. Most Active Players: Analysis by Number of Funding Instances
12.3.9. Most Active Players: Analysis by Total Amount Raised
12.3.10. Most Active Investors: Analysis by Number of Funding Instances
12.3.11. Analysis of Amount Invested by Year and Type of Funding (Grid Representation)
13. PATENT ANALYSIS
13.1. Chapter Overview
13.2. Scope and Methodology
13.3. mRNA Therapeutics and mRNA Vaccines: Patent Analysis
13.3.1. Analysis by Type of Patent
13.3.2. Analysis by Patent Publication Year
13.3.3. Analysis of Granted Patents by Publication Year
13.3.4. Analysis of Filed Patents by Publication Year
13.3.5. Analysis of Year-wise Filed Patent Applications and Granted Patents
13.3.6. Analysis by Publication Year and Type of Applicant
13.3.7. Analysis by Patent Issuing Authority
13.3.8. Analysis by Patent Age
13.3.9. Analysis by CPC Symbols
13.3.10. Leading Players: Analysis by Number of Patents
13.3.11. Leading Inventors: Analysis by Number of Patents
13.4. mRNA Therapeutics and mRNA Vaccines: Patent Benchmarking Analysis
13.4.1. Analysis by Patent Characteristics
13.5. mRNA Therapeutics and mRNA Vaccines: Patent Valuation Analysis
14. MARKET FORECAST AND OPPORTUNITY ANALYSIS
14.1. Chapter Overview
14.2. Key Assumptions and Methodology
14.3. Global mRNA Therapeutics and mRNA Vaccine Market, 2022-2035
14.3.1. mRNA Therapeutics and mRNA Vaccine Market: Analysis by Route of Administration, 2022, 2030, 2035
14.3.2. mRNA Therapeutics and mRNA Vaccine Market: Analysis by Therapeutic Area, 2022, 2030, 2035
14.3.3. mRNA Therapeutics and mRNA Vaccine Market: Analysis by Geography, 2022, 2030, 2035
14.3.3.1. mRNA Therapeutics and mRNA Vaccine Market in North America, 2022-2035
14.3.3.2. mRNA Therapeutics and mRNA Vaccine Market in Europe, 2022-2035
14.3.3.3. mRNA Therapeutics and mRNA Vaccine Market in Asia-Pacific, 2022-2035
14.3.3.4. mRNA Therapeutics and mRNA Vaccine Market in Latin America, 2022-2035
14.3.3.5. mRNA Therapeutics and mRNA Vaccine Market in Middle East and North Africa, 2022-2035
14.4. mRNA Therapeutics and mRNA Vaccine Market: Value Creation Analysis
14.5. mRNA Therapeutics and mRNA Vaccine Market: Product-wise Sales Forecasts
14.5.1. COMIRNATY
14.5.1.1. Target Patient Population
14.5.1.2. Sales Forecast
14.5.1.3. Net Present Value
14.5.1.4. Value Creation Analysis
14.5.2. Spikevax
14.5.2.1. Target Patient Population
14.5.2.2. Sales Forecast
14.5.2.3. Net Present Value
14.5.2.4. Value Creation Analysis
14.5.3. GEMCOVAC-19
14.5.3.1. Target Patient Population
14.5.3.2. Sales Forecast
14.5.3.3. Net Present Value
14.5.3.4. Value Creation Analysis
14.5.4. ARCoV
14.5.4.1. Target Patient Population
14.5.4.2. Sales Forecast
14.5.4.3. Net Present Value
14.5.4.4. Value Creation Analysis
14.5.5. CVnCoV
14.5.5.1. Target Patient Population
14.5.5.2. Sales Forecast
14.5.5.3. Net Present Value
14.5.5.4. Value Creation Analysis
14.5.6. ARCT-154
14.5.6.1. Target Patient Population
14.5.6.2. Sales Forecast
14.5.6.3. Net Present Value
14.5.6.4. Value Creation Analysis
14.5.7. mRNA-1647
14.5.7.1. Target Patient Population
14.5.7.2. Sales Forecast
14.5.7.3. Net Present Value
14.5.7.4. Value Creation Analysis
14.5.8. mRNA-1345
14.5.8.1. Target Patient Population
14.5.8.2. Sales Forecast
14.5.8.3. Net Present Value
14.5.8.4. Value Creation Analysis
14.5.9. mRNA-1010
14.5.9.1. Target Patient Population
14.5.9.2. Sales Forecast
14.5.9.3. Net Present Value
14.5.9.4. Value Creation Analysis
15. CONCLUSION
16. INTERVIEW AND SURVEY TRANSCRIPTS
16.1. Chapter Overview
16.2. eTheRNA Immunotherapies
16.2.1. Company Snapshot
16.2.2. Interview Transcript: David Ricketts (Director, Business Development)
17. APPENDIX I: TABULATED DATA
18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
Figure 2.1 Executive Summary: Market Landscape
Figure 2.2 Executive Summary: Clinical Trial Analysis
Figure 2.3 Executive Summary: Partnerships and Collaborations
Figure 2.4 Executive Summary: Funding and Investment Analysis
Figure 2.5 Executive Summary: Patent Analysis
Figure 2.6 Executive Summary: Market Forecast and Opportunity Analysis
Figure 3.1 Historical Evolution of mRNA
Figure 3.2 Key Applications of mRNA Therapeutics
Figure 4.1 mRNA Therapeutics and mRNA Vaccines: Distribution by Phase of Development
Figure 4.2 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Drug Candidate
Figure 4.3 mRNA Therapeutics and mRNA Vaccines: Distribution by Therapeutic Area
Figure 4.4 mRNA Therapeutics and mRNA Vaccines: Distribution by Phase of Development and Therapeutic Area
Figure 4.5 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Delivery System Used
Figure 4.6 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Molecule Encoded
Figure 4.7 mRNA Therapeutics and mRNA Vaccines: Distribution by Route of Administration
Figure 4.8 mRNA Therapeutics and mRNA Vaccines: Distribution by Therapeutic Area and Route of Administration
Figure 4.9 mRNA Therapeutics and Vaccines: Distribution by Phase of Development, Therapeutic Area and Route of Administration
Figure 5.1 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Year of Establishment
Figure 5.2 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Company Size
Figure 5.3 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Location of Headquarters
Figure 5.4 Key Companies: Distribution by Number of Drug Candidates
Figure 5.5 Key Companies: Distribution by Phase of Development
Figure 5.6 Key Companies: Distribution by Therapeutic Area
Figure 5.7 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Year of Establishment, Company Size and Location of Headquarters
Figure 5.8 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Phase of Development and Location of Headquarters
Figure 6.1 Company Competitiveness Analysis: mRNA Therapeutics and mRNA Vaccine Companiesbased in North America
Figure 6.2 Company Competitiveness Analysis: mRNA Therapeutics and mRNA Vaccine Companies based in Europe
Figure 6.3 Company Competitiveness Analysis: mRNA Therapeutics and mRNA Vaccine Companies based in Asia-Pacific and Rest of the World
Figure 8.1 Big Pharma Players: Distribution of Top Pharmaceutical Companies
Figure 8.2 Big Pharma Players: Distribution by Portfolio Diversity
Figure 8.3 Big Pharma Players: Distribution by Phase of Development
Figure 8.4 Big Pharma Players: Distribution by Target Therapeutic Areas
Figure 8.5 Spider Web Analysis: Amgen
Figure 8.6 Spider Web Analysis: AstraZeneca
Figure 8.7 Spider Web Analysis: Bayer
Figure 8.8 Spider Web Analysis: BioNTech
Figure 8.9 Spider Web Analysis: Eli Lilly
Figure 8.10 Spider Web Analysis: Gilead Sciences
Figure 8.11 Spider Web Analysis: GlaxoSmithKline
Figure 8.12 Spider Web Analysis: Merck
Figure 8.13 Spider Web Analysis: Moderna
Figure 8.14 Spider Web Analysis: Novartis
Figure 8.15 Spider Web Analysis: Novo Nordisk
Figure 8.16 Spider Web Analysis: Pfizer
Figure 8.17 Spider Web Analysis: Roche
Figure 8.18 Spider Web Analysis: Sanofi
Figure 8.19 Spider Web Analysis: Takeda
Figure 9.1 Startup-Health Indexing: Distribution by Location of Headquarters
Figure 9.2 Startup-Health Indexing: Distribution by Supplier Strength
Figure 9.3 Startup-Health Indexing: Distribution by Pipeline Maturity
Figure 9.4 Startup-Health Indexing: Distribution by Pipeline Strength
Figure 9.5 Startup-Health Indexing: Distribution by Financial Investments
Figure 9.6 Startup-Health Indexing: Distribution by Partnership Activity
Figure 9.7 Start-up Health Indexing: Roots Analysis Perspective
Figure 9.8 Start-up Health Indexing: Leading Companies
Figure 10.1 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Figure 10.2 Clinical Trial Analysis: Distribution by Trial Status
Figure 10.3 Clinical Trial Analysis: Distribution by Trial Phase
Figure 10.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 10.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Figure 10.6 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Figure 10.7 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Figure 10.8 Clinical Trial Analysis: Distribution of Trials by Study Design
Figure 10.9 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 10.10 Most Active Players: Distribution by Number of Registered Trials
Figure 10.11 Clinical Trial Analysis: Distribution by Therapeutic Area
Figure 10.12 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Figure 10.13 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Figure 10.14 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Figure 11.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Figure 11.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 11.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 11.4 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 11.5 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 11.6 Most Active Players: Distribution by Number of Partnerships
Figure 11.7 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.8 Partnerships and Collaborations: Local and International Agreements
Figure 12.1 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Figure 12.2 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Figure 12.3 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Figure 12.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 12.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 12.6 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Figure 12.7 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Figure 12.8 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Figure 12.9 Most Active Players: Distribution by Number of Funding Instances
Figure 12.10 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 12.11 Most Active Investors: Distribution by Number of Funding Instances
Figure 12.12 Funding and Investment Analysis: Distribution of Amount Invested by Year and Type of Funding
Figure 13.1 Patent Analysis: Distribution by Type of Patent
Figure 13.2 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Figure 13.3 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Figure 13.4 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Figure 13.5 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Figure 13.6 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Figure 13.7 Patent Analysis: Distribution by Patent Issuing Authority
Figure 13.8 Patent Analysis: Distribution by Patent Age
Figure 13.9 Patent Analysis: Distribution by CPC Sections
Figure 13.10 Patent Analysis: Leading Industry Players
Figure 13.11 Patent Analysis: Leading Non-Industry Players
Figure 13.12 Leading Inventors: Distribution by Number of Patents
Figure 13.13 Patent Benchmarking: Distribution of Leading Industry Players by Patent Characteristics (CPC Codes)
Figure 13.14 mRNA Therapeutics and mRNA Vaccines: Patent Valuation
Figure 14.1 Global mRNA Therapeutics and mRNA Vaccine Market, 2022-2035 (USD Million)
Figure 14.2 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Route of Administration, 2022, 2035 and 2035
Figure 14.3 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Figure 14.4 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Geography, 2022, 2030 and 2035
Figure 14.5 mRNA Therapeutics and mRNA Vaccine Market in North America, 2022-2035 (USD Million)
Figure 14.6 mRNA Therapeutics and mRNA Vaccine Market in the US, 2022-2035 (USD Million)
Figure 14.7 mRNA Therapeutics and mRNA Vaccine Market in Canada, 2022-2035 (USD Million)
Figure 14.8 mRNA Therapeutics and mRNA Vaccine Market in Mexico, 2022-2035 (USD Million)
Figure 14.9 mRNA Therapeutics and mRNA Vaccine Market in Europe, 2022-2035 (USD Million)
Figure 14.10 mRNA Therapeutics and mRNA Vaccine Market in the UK, 2022-2035 (USD Million)
Figure 14.11 mRNA Therapeutics and mRNA Vaccine Market in France, 2022-2035 (USD Million)
Figure 14.12 mRNA Therapeutics and mRNA Vaccine Market in Germany, 2022-2035 (USD Million)
Figure 14.13 mRNA Therapeutics and mRNA Vaccine Market in Italy, 2022-2035 (USD Million)
Figure 14.14 mRNA Therapeutics and mRNA Vaccine Market in Spain, 2022-2035 (USD Million)
Figure 14.15 mRNA Therapeutics and mRNA Vaccine Market in Rest of Europe, 2022-2035 (USD Million)
Figure 14.16 mRNA Therapeutics and mRNA Vaccine Market in Asia-Pacific, 2022-2035 (USD Million)
Figure 14.17 mRNA Therapeutics and mRNA Vaccine Market in India, 2022-2035 (USD Million)
Figure 14.18 mRNA Therapeutics and mRNA Vaccine Market in China, 2022-2035 (USD Million)
Figure 14.19 mRNA Therapeutics and mRNA Vaccine Market in Japan, 2022-2035 (USD Million)
Figure 14.20 mRNA Therapeutics and mRNA Vaccine Market in Australia, 2022-2035 (USD Million)
Figure 14.21 mRNA Therapeutics and mRNA Vaccine Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Figure 14.22 mRNA Therapeutics and mRNA Vaccine Market in Latin America, 2022-2035 (USD Million)
Figure 14.23 mRNA Therapeutics and mRNA Vaccine Market in Middle East and North Africa, 2022-2035 (USD Million)
Figure 14.24 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.25 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.26 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.27 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.28 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.29 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.30 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.31 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 14.32 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Figure 15.1 Concluding Remarks: Overall Market Landscape
Figure 15.2 Concluding Remarks: Partnerships and Collaborations
Figure 15.3 Concluding Remarks: Funding and Investment Analysis
Figure 15.4 Concluding Remarks: Clinical Trial Analysis
Figure 15.5 Concluding Remarks: Patent Analysis
Figure 15.6 Concluding Remarks: Market Forecast and Opportunity Analysis
Table 4.1 mRNA Therapeutics and mRNA Vaccines: Overall Market Overview
Table 4.2 mRNA Therapeutics and mRNA Vaccines: Information on Type of Delivery System Used
Table 4.3 mRNA Therapeutics and mRNA Vaccines: Information on Type of Molecule Encoded
Table 4.4 mRNA Therapeutics and mRNA Vaccines: Information on Route of Administration
Table 5.1 mRNA Therapeutics and mRNA Vaccines: List of Companies
Table 7.1 Drug Profile: BNT162b2
Table 7.2 Drug Profile: mRNA-1273
Table 7.3 Drug Profile: GEMCOVAC-19
Table 7.4 Drug Profile: ARCoV
Table 7.5 Drug Profile: LUNAR-COV19
Table 7.6 Drug Profile: CVnCoV
Table 7.7 Drug Profile: mRNA-1010
Table 7.8 Drug Profile: mRNA-1345
Table 7.9 Drug Profile: mRNA-1647
Table 9.1 mRNA Therapeutics and mRNA Vaccines Start-ups: Information on Location of Headquarters
Table 11.1 mRNA Therapeutics and mRNA Vaccines: List of Partnerships and Collaborations
Table 11.2 mRNA Therapeutics and mRNA Vaccines: Information on Type of Agreement (Region-wise and Geography-wise), 2013-2022
Table 12.1 mRNA Therapeutics and mRNA Vaccines: List of Funding and Investments
Table 13.1 Patent Analysis: Top CPC Sections
Table 13.2 Patent Analysis: Top CPC Symbols
Table 13.3 Patent Analysis: Top CPC
Table 13.4 Patent Portfolio: Summary of Benchmarking Analysis
Table 13.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 13.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 14.1 mRNA Therapeutics and mRNA Vaccines: Expected Launch Year of Advance Stage Drug Candidates
Table 14.2 Comirnaty: Target Patient Population
Table 14.3 Comirnaty: Net Present Value (USD Million)
Table 14.4 Comirnaty: Value Creation Analysis (USD Million)
Table 14.5 Spikevax: Target Patient Population
Table 14.6 Spikevax: Net Present Value (USD Million)
Table 14.7 Spikevax: Value Creation Analysis (USD Million)
Table 14.8 GEMCOVAC-19: Target Patient Population
Table 14.9 GEMCOVAC-19: Net Present Value (USD Million)
Table 14.10 GEMCOVAC-19: Value Creation Analysis (USD Million)
Table 14.11 ARCoV: Target Patient Population
Table 14.12 ARCoV: Net Present Value (USD Million)
Table 14.13 ARCoV: Value Creation Analysis (USD Million)
Table 14.14 CVnCoV: Target Patient Population
Table 14.15 CVnCoV: Net Present Value (USD Million)
Table 14.16 CVnCoV: Value Creation Analysis (USD Million)
Table 14.17 ARCT-154: Target Patient Population
Table 14.18 ARCT-154: Net Present Value (USD Million)
Table 14.19 ARCT-154: Value Creation Analysis (USD Million)
Table 14.20 mRNA-1345: Target Patient Population
Table 14.21 mRNA-1345: Net Present Value (USD Million)
Table 14.22 mRNA-1345: Value Creation Analysis (USD Million)
Table 14.23 mRNA-1647: Target Patient Population
Table 14.24 mRNA-1647: Net Present Value (USD Million)
Table 14.25 mRNA-1647: Value Creation Analysis (USD Million)
Table 14.26 mRNA-1010: Target Patient Population
Table 14.27 mRNA-1010: Net Present Value (USD Million)
Table 14.28 mRNA-1010: Value Creation Analysis (USD Million)
Table 16.1 eTheRNA: Key Highlights
Table 17.1 mRNA Therapeutics and mRNA Vaccines: Distribution by Phase of Development
Table 17.2 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Drug Candidate
Table 17.3 mRNA Therapeutics and mRNA Vaccines: Distribution by Therapeutic Area
Table 17.4 mRNA Therapeutics and mRNA Vaccines: Distribution by Phase of Development and Therapeutic Area
Table 17.5 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Delivery System Used
Table 17.6 mRNA Therapeutics and mRNA Vaccines: Distribution by Type of Molecule Encoded
Table 17.7 mRNA Therapeutics and mRNA Vaccines: Distribution by Route of Administration
Table 17.8 mRNA Therapeutics and mRNA Vaccines: Distribution by Therapeutic Area and Route of Administration
Table 17.9 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Year of Establishment
Table 17.10 mRNA Therapeutics and mRNA Vaccine Companies: Distribution by Company Size
Table 17.11 mRNA Therapeutics and mRNA VaccineCompanies: Distribution by Location of Headquarters
Table 17.12 Key Companies: Distribution by Number of Drug Candidates
Table 17.13 Key Companies: Distribution by Phase of Development
Table 17.14 Key Companies: Distribution by Therapeutic Area
Table 17.15 Big Pharma Players: Distribution by Portfolio Diversity
Table 17.16 Big Pharma Players: Distribution by Phase of Development
Table 17.17 Big Pharma Players: Distribution by Target Therapeutic Areas
Table 17.18 Startup-Health Indexing: Distribution by Location of Headquarters
Table 17.19 Startup-Health Indexing: Distribution by Supplier Strength
Table 17.20 Startup-Health Indexing: Distribution by Pipeline Maturity
Table 17.21 Startup-Health Indexing: Distribution by Pipeline Strength
Table 17.22 Startup-Health Indexing: Distribution by Financial Investments
Table 17.23 Startup-Health Indexing: Distribution by Partnership Activity
Table 17.24 Clinical Trial Analysis: Distribution by Trial Registration Year, Pre-2017-2022
Table 17.25 Clinical Trial Analysis: Distribution by Trial Status
Table 17.26 Clinical Trial Analysis: Distribution by Trial Phase
Table 17.27 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 17.28 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Phase
Table 17.29 Clinical Trial Analysis: Distribution by Trial Status and Trial Phase
Table 17.30 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Trial Registration Year
Table 17.31 Clinical Trial Analysis: Distribution by Study Design
Table 17.32 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 17.33 Most Active Players: Distribution by Number of Registered Trials
Table 17.34 Clinical Trial Analysis: Distribution by Therapeutic Area
Table 17.35 Clinical Trial Analysis: Distribution by Number of Registered Trials and Geography
Table 17.36 Clinical Trial Analysis: Distribution by Number of Registered Trials, Trial Status and Geography
Table 17.37 Clinical Trial Analysis: Distribution of Enrolled Patient Population by Geography
Table 17.38 Partnerships and Collaborations: Cumulative Year-wise Trend, 2013-2022
Table 17.39 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 17.41 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 17.42 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 17.43 Most Active Players: Distribution by Number of Partnerships
Table 17.44 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 17.45 Partnerships and Collaborations: Local and International Agreements
Table 17.46 Funding and Investment Analysis: Cumulative Year-wise Trend of Funding Instances, Pre-2015 - 2022
Table 17.47 Funding and Investment Analysis: Cumulative Year-wise Trend of Amount Invested, Pre-2015 - 2022 (USD Million)
Table 17.48 Funding and Investment Analysis: Distribution of Instances by Type of Funding
Table 17.49 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Table 17.50 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 17.51 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Therapeutic Area
Table 17.52 Funding and Investment Analysis: Distribution of Instances and Amount Invested by Geography (Continent-wise)
Table 17.53 Funding and Investment Analysis: Regional Distribution of Instances (Country-wise)
Table 17.54 Most Active Players: Distribution by Number of Funding Instances
Table 17.55 Most Active Players: Distribution by Total Amount Raised
Table 17.56 Most Active Investors: Distribution by Number of Funding Instances
Table 17.57 Patent Analysis: Distribution by Type of Patent
Table 17.58 Patent Analysis: Cumulative Distribution by Patent Publication Year, 2016-2022
Table 17.59 Patent Analysis: Cumulative Distribution of Granted Patents by Publication Year, 2016-2022
Table 17.60 Patent Analysis: Cumulative Distribution of Filed Patent Applications by Publication Year, 2016-2022
Table 17.61 Patent Analysis: Distribution by Year-wise Filed Patent Applications and Granted Patents, 2016-2022
Table 17.62 Patent Analysis: Cumulative Distribution of Patents by Publication Year and Type of Applicant, 2016-2022
Table 17.63 Patent Analysis: Distribution by Patent Issuing Authority
Table 17.64 Patent Analysis: Distribution by Patent Age
Table 17.65 Patent Analysis: Leading Industry Players
Table 17.66 Patent Analysis: Leading Non-Industry Players
Table 17.67 Leading Inventors: Distribution by Number of Patents
Table 17.68 mRNA Therapeutics and mRNA Vaccines: Patent Valuation
Table 17.69 Global mRNA Therapeutics and mRNA Vaccine Market, 2022-2035 (USD Million)
Table 17.70 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Route of Administration, 2022, 2030 and 2035
Table 17.71 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Therapeutic Area, 2022, 2030 and 2035
Table 17.72 mRNA Therapeutics and mRNA Vaccine Market: Distribution by Geography
Table 17.73 mRNA Therapeutics and mRNA Vaccine Market in North America, 2022-2035 (USD Million)
Table 17.74 mRNA Therapeutics and mRNA Vaccine Market in the US, 2022-2035 (USD Million)
Table 17.75 mRNA Therapeutics and mRNA Vaccine Market in Canada, 2022-2035 (USD Million)
Table 17.76 mRNA Therapeutics and mRNA Vaccine Market in Mexico, 2022-2035 (USD Million)
Table 17.77 mRNA Therapeutics and mRNA Vaccine Market in Europe, 2022-2035 (USD Million)
Table 17.78 mRNA Therapeutics and mRNA Vaccine Market in the UK, 2022-2035 (USD Million)
Table 17.79 mRNA Therapeutics and mRNA Vaccine Market in France, 2022-2035 (USD Million)
Table 17.80 mRNA Therapeutics and mRNA Vaccine Market in Germany, 2022-2035 (USD Million)
Table 17.81 mRNA Therapeutics and mRNA Vaccine Market in Italy, 2022-2035 (USD Million)
Table 17.82 mRNA Therapeutics and mRNA Vaccine Market in Spain, 2022-2035 (USD Million)
Table 17.83 mRNA Therapeutics and mRNA Vaccine Market in Rest of Europe, 2022-2035 (USD Million)
Table 17.84 mRNA Therapeutics and mRNA Vaccine Market in Asia-Pacific, 2022-2035 (USD Million)
Table 17.85 mRNA Therapeutics and mRNA Vaccine Market in India, 2022-2035 (USD Million)
Table 17.86 mRNA Therapeutics and mRNA Vaccine Market in China, 2022-2035 (USD Million)
Table 17.87 mRNA Therapeutics and mRNA Vaccine Market in Japan, 2022-2035 (USD Million)
Table 17.88 mRNA Therapeutics and mRNA Vaccine Market in Australia, 2022-2035 (USD Million)
Table 17.89 mRNA Therapeutics and mRNA Vaccine Market in Rest of Asia-Pacific, 2022-2035 (USD Million)
Table 17.90 mRNA Therapeutics and mRNA Vaccine Market in Latin America, 2022-2035 (USD Million)
Table 17.91 mRNA Therapeutics and mRNA Vaccine Market in Middle East and North Africa, 2022-2035 (USD Million)
Table 17.92 Comirnaty Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.93 Spikevax Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.94 GEMCOVAC-19 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.95 ARCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.96 CVnCoV Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.97 ARCT-154 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.98 mRNA-1345 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.99 mRNA-1647 Sales Forecast: Base Scenario, Till 2035 (USD Million)
Table 17.100 mRNA-1010 Sales Forecast: Base Scenario, Till 2035 (USD Million)
The following companies and organizations have been mentioned in the report: